Analysis of the Immune Efficacy and Influencing Factors of Different Dose of Hepatitis B Vaccine in Patients with Lymphoma.
10.7534/j.issn.1009-2137.2019.06.024
- Author:
Mao-Juan HUANG
1
;
Wei-Huang ZHUANG
2
Author Information
1. Department of Laboratorial Examination, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, FuJian Province, China.
2. Department of Hematology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, FuJian Province, China,E-mail: 13808521170@163.com.
- Publication Type:Journal Article
- MeSH:
Female;
Hepatitis B;
Hepatitis B Antibodies;
Hepatitis B Surface Antigens;
Hepatitis B Vaccines;
Hepatitis B virus;
Humans;
Lymphoma;
therapy
- From:
Journal of Experimental Hematology
2019;27(6):1856-1861
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the conversion rate from negative to positive (positive rate) of HBsAb in lymphoma patients inoculated with different dose of hepatitis B vaccine, to evaluate the immune efficacy of different dose of hepatitis B vaccine, and to analyze the influencing factors.
METHODS:Two hundred thirty six patients with lymphoma were selected, whose 5 indexes of hepatitis B (HBsAg, HBsAb, HBeAg, HBeAb and HBcAb) were all negative confirmed by ELISA. The hepatitis B vaccine was inoculated according to 0, 1 and 6 months immune procedures at 1-2 weeks before chemotherapy. The HBsAb level was detected at 1 month after the immunization, the differences in each indexes between HBeAb and HBeAb patients were compared.
RESULTS:The positive rate of HBsAb was 75% in all patients with lymphoma.The positive rate of high dose (20 μg) group was 81.4%, which was significantly higher than that of the low dose (10μg) group with 68.6% (χ=5.09, P＜0.05). The positive conversion rate of HBsAb significantly higher in the patients of young, female, B-cell (except DLBCL subtype), early Ann Arbor stage, and the treatment regimens without glucocorticoid and rituximab. There were no statistical significances in systemic symptoms or no and treatment regimens with or without lenalidomide. Two doses of hepatitis B vaccine not displayed obvious adverse reactions.
CONCLUSION:The high dose of hepatitis B vaccine can achieve better immune efficacy than that of the low dose in the patients with lymphoma.
